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ABSTRACT 
 
Purpose: The use of neural networks to directly predict three-dimensional dose distributions 
for automatic planning is becoming popular. However, the existing methods use only patient 
anatomy as input and assume consistent beam configuration for all patients in the training 
database. The purpose of this work is to develop a more general model that considers 
variable beam configurations in addition to patient anatomy to achieve more comprehensive 
automatic planning with a potentially easier clinical implementation, without the need to train 
specific models for different beam settings.  
Methods: The proposed anatomy and beam (AB) model is based on our newly developed 
deep learning architecture, hierarchically densely connected U-Net (HD U-Net), which 
combines U-Net and DenseNet. The AB model contains 10 input channels, one for beam 
setup and the other 9 for anatomical information (PTV and organs). The beam setup 
information is represented by a 3D matrix of the non-modulated beam’s eye view ray-tracing 
dose distribution. We used a set of images from 129 patients with lung cancer treated with 
IMRT with heterogeneous beam configurations (4 to 9 beams of various orientations) for 
training/validation (100 patients) and testing (29 patients). Mean squared error was used as 
the loss function. We evaluated the model’s accuracy by comparing the mean dose, 
maximum dose, and other relevant dose-volume metrics for the predicted dose distribution 
against those of the clinically delivered dose distribution. Dice similarity coefficients were 
computed to address the spatial correspondence of the isodose volumes between the 
predicted and clinically delivered doses. The model was also compared with our previous 
work, the anatomy only (AO) model, which does not consider beam setup information and 
uses only 9 channels for anatomical information. 
Results: The AB model outperformed the AO model, especially in the low and medium dose 
regions. In terms of dose volume metrics, AB outperformed AO is about 1-2%. The largest 
improvement was found to be about 5% in lung volume receiving a dose of 5 Gy or more 
(V5). The improvement for spinal cord maximum dose was also important, i.e., 3.6% for 
cross-validation and 2.6% for testing. The AB model achieved Dice scores for isodose 
volumes as much as 10% higher than the AO model in low and medium dose regions and 
about 2% to 5% higher in high dose regions.  
Conclusions: The AO model, which does not use beam configuration as input, can still 
predict dose distributions with reasonable accuracy in high dose regions but introduces large 
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errors in low and medium dose regions for IMRT cases with variable beam numbers and 
orientations. The proposed AB model outperforms the AO model substantially in low and 
medium dose regions and slightly in high dose regions by considering beam setup 
information through a cumulative non-modulated beam’s eye view ray-tracing dose 
distribution. This new model represents a major step forward towards predicting 3D dose 
distributions in real clinical practice, where beam configuration could vary from patient to 
patient, from planner to planner, and from institution to institution.  
 
 
 
1. INTRODUCTION 
 
Current treatment planning systems for radiation therapy use advanced software to 
solve an inverse optimization problem,1 which aims to determine the optimal treatment and 
machine parameters from an a priori specified set of dose objectives for the target and 
organs at risk (OARs). The fastest software can provide a solution to this problem within 
seconds. However, the medical physicist or dosimetrist still fine tunes the dose objectives 
manually until the desired dose distribution is achieved. This results in a heuristic and time-
consuming process (from several hours to days), which entails a variability2–4 in plan quality 
that depends on factors such as the time available to generate the plan, the institution 
guidelines, or the planner’s skills. This variability may lead to suboptimal plans that can 
compromise the final treatment outcome.5–7 Furthermore, the extended treatment planning 
time greatly hinders the implementation of adaptive strategies8, 9 and may delay treatment 
delivery, both of which have a negative impact on tumor control and patients’ quality of 
life.10–13  
To overcome these problems, the research community has concentrated its efforts 
on reducing this manual component by automating the treatment planning process. Several 
groups have come up with powerful solutions that can be classified into two branches. The 
first branch, here referred to as objective-based planning (OBP), relies on optimization 
algorithms that adjust pre-set objectives to achieve the established clinical goals, with well-
known implementations including the in-house software Erasmus-iCycle14 or the Auto-
Planning Engine15 commercialized by Pinnacle (Philips Radiation Oncology, Fitchburg, WI), 
among others.16–19 The second branch, what is called knowledge-based planning (KBP), 
uses a library of plans from previous patients to predict dose volume objectives for the new 
patient20–23 and is best exemplified by the popular commercial solution RapidPlan (Varian 
Medical Systems, Palo Alto, CA). All these alternatives for automatic planning have been 
tested in different patient populations and anatomical sites, and they have sped up the 
planning process considerably (time reduction of 70-90%) for both intensity modulated 
radiation therapy (IMRT) and volumetric arc therapy (VMAT)24–26 while generating high-
quality plans with less human intervention.27–31  
Even with these advancements, the OBP and KBP methods still suffer from two main 
drawbacks. First, they use dose volume objectives, either zero-dimensional (dose volume 
points) or one-dimensional (dose volume histogram, DVH), for the delineated structures. 
These dose volume objectives are insensitive to spatial variations of the dose within the 
structures delineated and blind to those structures that are not delineated. This could lead to 
suboptimal plans, in terms of the spatial distribution of the dose, and may require post-
processing steps in which the user manually adds planning-aid structures and re-optimizes 
to control these spatial features. Second, both OBP and KBP strategies still require 
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substantial human intervention to define certain parameters needed to create the model, 
such as the target and OAR optimization goals for OBP14, 29, 32 or  handcrafted features that 
serve to match the actual patient to those in the library of patients for KBP.20, 32, 33 Including 
spatial dose information34–42 and completely removing manually extracted features are 
necessary to achieve a more individualized and comprehensive automatic planning. 
The recent evolution of deep learning methods has motivated the use of 
convolutional neural networks (CNN) to predict patient-specific voxel-wise dose distributions 
from anatomical information (i.e., contours and/or CT), either in a slice-by-slice manner 
(2D)39–41, 43 or directly as a 3D matrix.38, 42, 44 The predicted dose distribution can later be 
used as an objective to automatically generate a treatment plan.37, 45 These methods 
completely eliminate dependence on handcrafted features by allowing the deep network to 
learn its own features for prediction,38–42 and the results reported so far are very promising. 
However, the performance of these deep learning methods for voxel-wise dose prediction 
strongly depends on the database used for training, requiring users to carefully choose 
patients with consistent beam configurations, such as VMAT38 or IMRT, with fixed and 
equally spaced beams.39–41 This ensures an accurate dose prediction for cases with similar 
beam settings, but it impedes the generalization of the model to more heterogeneous beam 
configurations, which is crucial for IMRT treatments where the beam number and 
orientations could vary greatly from patient to patient and from institution to institution. As a 
result, the clinical implementation of automatic planning based on this type of model appears 
to be unfeasible, since it would require generating specific models for each individual beam 
arrangement.  
The current models38–42 use only anatomical information as inputs to the CNN. In this 
work, we investigate the value of including both anatomical and beam setup information in 
the network, to build a single model that is robust to variable beam configurations. This 
general model can realize the full potential of deep neural networks for dose prediction, 
bringing closer the clinical implementation of automatic planning based on this type of 
method.  
 
2.  MATERIALS AND METHODS 
 
2. A. Model architecture 
 
The model used for dose prediction was developed in-house, and its architecture is 
based on the popular U-Net, published by Ronneberger et al. in 2015.46 The U-Net is a type 
of CNN that belongs to the class of fully convolutional networks,47 and it can include both 
local and global features from the input images to generate a pixel-wise (two-dimensional, 
2D) prediction. Our group has previously used this architecture to generate 2D dose 
predictions for prostate patients in a slice-by-slice manner.39 However, to avoid errors in the 
superior and inferior borders of the planning target volume (PTV) and OARs inherent to this 
2D strategy, we developed a three-dimensional (3D) variant of the classical 2D U-Net. Since 
the computational load increases with the dimensionality, our group created different models 
to achieve an accurate and efficient 3D dose prediction. These models are described in 
detail elsewhere38 and have been tested for head and neck patients. The best performance 
was achieved by a model that combined two recently proposed architectures: DenseNet by 
Huang et al. in 201748 and V-Net by Milletari et al. in 2016.49 The DenseNet densely 
connects its convolutional layers in a feed-forward fashion, using the feature-maps of all 
preceding layers as inputs for the current layer. This reduces the vanishing-gradient 
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problem, enhances feature propagation and reuse, and decreases the number of trainable 
parameters. The drawback of this approach is its increased memory usage, a consequence 
of the dense connection between layers. To maintain a reasonable RAM usage, we modified 
the DenseNet to skip some connections between groups of layers, following the work of 
Milletari et al. In addition, Huang et al.48 found that DenseNet architectures could utilize 
considerably fewer trainable parameters than non-densely connected architectures, yielding 
better RAM usage and better generalization of the model that outweighs the greater RAM 
consumption of the dense connections themselves. In particular, the convolutional layers in 
our model are densely connected within levels of the same resolution in the U-Net, between 
each max pooling and up-sampling operation. We refer to each of these levels as a 
“hierarchy,” which motivated us to name this network “Hierarchically Densely Connected U-
Net” (“HD U-Net”38). This HD U-Net combines DenseNet’s efficient feature propagation and 
reuse with U-Net’s ability to infer the global and local image information, while maintaining a 
reasonable memory usage. The detailed architecture of the HD U-Net used in this study is 
presented in Figure 1, and the technical elements regarding the operations between layers 
have been previously described elsewhere.38, 44  The HD U-Net uses the Adam optimization 
algorithm to minimize the mean squared error (MSE) between the predicted dose (Dpred) and 
the clinically delivered dose (Dc) during training, i.e., MSE = 
!" (𝐷%&'() − 𝐷+))-").! , where i is 
the index of the voxel and n is the total number of voxels. The network combines the three 
operations in the legend: dense convolution, dense downsampling, and U-Net upsampling. 
The dense convolution uses a standard convolution with the well-known Rectified Linear Unit 
(ReLU50) as its activation function, followed by a concatenation of the previous feature map. 
The dense downsampling uses a strided convolution and ReLU to compute a new feature 
map with half of the former resolution. Max pooling is applied to the previous feature map, 
which is then concatenated to the new feature map. The U-Net upsampling consists of 
upsampling, convolution, and ReLU, followed by a concatenation of the feature map on the 
other side of the “U.”  The activation function at the last output layer was also ReLU. We did 
not apply any regularization method during training, i.e. the dropout rate was set to zero, and 
there was no batch normalization.  
The model proposed in this work, called the Anatomy and Beam (AB) model, 
considers both patient anatomy and beam setup information as inputs. Hence, it contains 10 
input channels (Figure 1): one channel for beam setup information and 9 channels for 
anatomical information. The beam setup information is represented by an approximate 3D 
cumulative dose distribution (ray-tracing style, beam’s eye view, and non-modulated) from all 
involved beams (see Section 2.D). The anatomical information comprises 3D binary matrices 
or masks, i.e., the prescription dose (60 Gy) for voxels inside and 0 for voxels outside the 
PTV, and 1 for voxels inside and 0 for voxels outside each of the 8 relevant OARs for lung 
treatment planning: body, heart, esophagus, spinal cord, right and left lungs, both lungs 
minus the target, and carina. For some patients, certain organs are not delineated, and 
therefore, the corresponding channel receives an empty entry. 
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Figure 1. Architecture of the HD U-Net used in this study. Black numbers on the left side of the 
model represent the volume shape and resolution at a specific hierarchy. Red numbers represent the 
number of feature maps at a particular layer. Orange features represent the newly calculated 
features and trainable parameters to learn, while blue features are copied or max pooled features 
that do not need trainable parameters. The number of features (red numbers) represented here 
corresponds to the model and includes both anatomical and beam setup information (AB model, 10 
input channels).  
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2. B. Patient database 
 
The database consisted of images from 129 patients with lung cancer treated with 
IMRT at UT Southwestern Medical Center, which involved four different treating physicians. 
The database was heterogeneous in terms of number of beams (4 to 9 beams, all coplanar), 
beam orientation (Figure 2 and 3), and beam energy (6 and 10 MV). The clinically delivered 
dose and the contours for each patient were extracted from two different treatment planning 
systems: Pinnacle V8.0-V9.6 (Philips Radiation Oncology Systems, Fitchburg, WI) for 
patients treated before 2017 and Eclipse V13.7-V15.5 (Varian Medical Systems, Palo Alto, 
CA) for patients treated after 2017. All plans were created and calculated with heterogeneity 
correction. The target dose prescription for all patients was 60 Gy, delivered with two 
different fractionation protocols: 4 Gy x 15 fractions and 2 Gy x 30 fractions. The original 
IMRT dose and the contour masks for all patients were resampled to have a voxel resolution 
of 5x5x5 mm3. 
 
 
 
 
Figure 2. Number of patients per beam configuration (ranging from 4 to 9 beams) used for training 
(upper bar), validation (middle bar), and testing (lower bar).  
 
 
 
 
Figure 3. Examples of the different beam configurations from the patient database (test set). The 
yellow contours represent the PTV volume, and the color wash represents the dose distribution. 
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2. C. Model performance 
 
To evaluate the model’s performance and stability, we divided the database into two 
sets: 1) 100 patients for training and cross-validation (Figure 2, upper and middle bars), and 
2) 29 patients for testing (Figure 2, lower bars). A 5-fold cross-validation procedure was 
applied to the 100 patient set, which was itself split into 80 patients for training and 20 
patients for validation (Figure 2), alternating the latter along the 5 folds. When partitioning 
the dataset, we tried to balance the number of patients per beam configuration in the three 
sets: training, validation, and testing (Figure 2). The number of patients per beam 
configuration class was the same for each cross-validation fold. At every iteration, the 
network weights were updated based on the 80 training patients, and the loss function 
(MSE, see section 2.A.) was computed on the validation set. We investigated different 
numbers of iterations (epochs), from 100 to 1000, to find the best trade-off between 
optimality and training time. Since different MSE values might not directly translate into the 
same dose distribution quality, we also computed and analyzed relevant DVH metrics to 
decide the optimal number of epochs to use. Once this optimal number of epochs was found 
(i.e., the clinical metrics did not improve with further training), the final model was selected 
as the one that corresponded to the iteration with the lowest validation loss, to avoid 
overfitting to the training data.51 This process as repeated for each fold, generating 5 final 
models that were then evaluated in the testing dataset. All these operations were performed 
on an NVIDIA TESLA K80 GPU with 12 GB dedicated RAM. 
We also compared the AB model with our previous work and the current state-of-the-
art, the Anatomy Only (AO) model, which contains 9 input channels for the PTV and the 
organs, without the beam setup information. We evaluated the accuracy of the two methods 
(AB and AO) by computing the average error between the predicted (Dp,AB and Dp,AO) and 
clinically delivered (Dc) dose distributions on the mean and maximum dose values for 
different organs. We also analyzed the average error on relevant DVH metrics, such as the 
lung volume receiving a dose of at least 20 Gy (V20) or the dose delivered to 95% of the 
target volume (D95). All these values are presented as a percentage of the prescribed target 
dose (60 Gy). For easier comparison among patients, all doses (Dp,AB, Dp,AO, and Dc) were 
normalized to have an average dose inside the PTV equal to the prescription dose, i.e., 
Dmean = 60 Gy. This normalization point serves only as a fixed point for comparison, but the 
user can later shift the dose to any other convenient reference, such as the D95 of PTV equal 
to the prescription dose, which is often used in the clinic. We also evaluated the target dose 
homogeneity using the following equation for the homogeneity index: HI = (D2-D98)/D50. In 
addition, Dice similarity coefficients (DSC) of the isodose volumes from 5% to 95% of the 
prescription dose were computed for Dp,AB and Dp,AO and compared with those for Dc to 
evaluate the accuracy of the spatial distribution of the doses predicted by the two models. 
For this purpose, three-dimensional binary masks were computed for each isodose volume 
containing all voxels with a dose greater than or equal to the N% of the prescription dose, in 
both the predicted dose (Y) and the clinically delivered doses (X). Once we had these three-
dimensional binary masks (X and Y), the following operation was performed: DSC = - /∩1/ 2 1 . 
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2. D. Beam configuration representation  
 
The proposed architecture (section 2.A) aims to improve the accuracy and robustness of 
dose prediction against a database that is heterogeneous with regard to beam arrangement. 
The key here is to best represent the beam configuration without greatly complicating the 
model architecture and, in the meantime, to provide valuable information for accurate dose 
distribution prediction. Ideally, a good representation should be in the dose domain and 
contain information about beam energy, beam aperture, and heterogeneity correction, while 
being computationally inexpensive. For this purpose, we use a cumulative dose distribution 
computed using a ray-tracing type of algorithm for all beams in the plan, without modulation, 
and with apertures conformal to the PTV in beam’s eye view. We use a fluence-convolution 
broad-beam (FCBB) dose calculation method,52, 53 which is a modified ray-tracing algorithm, 
involving a 2D convolution of a fluence map with a lateral spread function followed by ray-
tracing based on the central axis of the beam. In our case, a dummy homogeneous fluence 
map (i.e., all weights equal to 1) with the aperture of the PTV projection in beam’s eye view 
plus an isotropic margin of 5 mm is generated for each beam angle. The FCBB dose engine 
then uses this dummy fluence map as input, together with percentage depth dose (PDD) 
profiles from the Golden Beam Data (GBD)54 provided by Varian Medical Systems, Inc. (Palo 
Alto, CA),54 to compute the non-modulated dose per beam. The algorithm can generate the 
dose per beam in fractions of a second. Since the final computed dose per beam is given in 
arbitrary units, a normalization is performed after summing up all beams to make the mean 
dose inside the PTV equal the prescription dose. After adding up the dose corresponding to 
every beam, all voxels inside the PTV are overwritten to have a dose equal to the 
prescription dose.  
Note that this study assumes that the number of beams and their orientations have 
been previously determined by the planner, as is commonly done in clinical practice, or will 
eventually be given by any beam angle optimization algorithm.  
 
2. E. Additional testing 
 
To further test the performance of our AB model for patients with beam 
configurations other than the ones included in the database described in section 2.B. (Figure 
2), we used three more patients with the following beam setups: patient #1) three coplanar 
beams, patient #2) eleven coplanar beams, and patient #3) ten non-coplanar beams. We 
evaluated and compared the AB and AO models on these three patients, using the same 
criteria as listed in section 2.C., i.e. relevant DVH metrics, HI, and Dice coefficients for the 
isodose volumes.  
 
3.  RESULTS  
 
The results for the average absolute error and its standard deviation (SD) on the mean 
and maximum dose for the target and OARs are presented in Figure 4 for cross-validation 
(average prediction on the validation set for all 5 folds) and in Figure 5 for testing (average 
prediction on the test set for all 5 folds). In both cases, the error on the mean and maximum 
doses predicted by the AB model was (on average) around 1% lower than on the AO model. 
The mean dose error value for the test set, averaged across all organs, was 2.28±2.01% on 
the AO model and 1.39±1.27% on the AB model. Likewise, the mean error on the maximum 
dose for the test set, averaged across all organs, was 3.97±4.73 % for the AO model and 
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2.85±3.06 % for the AB model. The biggest difference was found for the spinal cord 
maximum dose, where the AB model’s prediction error was up to 3.6% lower for cross-
validation and 2.6% lower for testing than the AO model’s. Table 1 reports some relevant 
DVH metrics commonly used in the clinic to evaluate lung IMRT treatments, predicted from 
the two models. Again, the AB model outperformed the AO model, with better prediction 
accuracy for all the DVH metrics considered. Although the difference in the mean average 
error for most metrics is rather low (around 1 - 1.5%), for other metrics such as the lung V20 
or V5, the error was up to 2% and 5% lower, respectively. The spinal cord D2 was also 
substantially lower (around 3%).  
The two models predicted the dose distribution in the target volume with equivalent 
accuracy, with homogeneity index (HI, mean±SD) equal to 0.11±0.02 for the AO model and 
0.08±0.02 for the AB model, versus 0.09±0.04 for the clinical doses, for cross-validation. 
Similar results were obtained for testing: HI equal to 0.10±0.03 for the AO model and 
0.08±0.02 for the AB model, versus 0.09±0.03 for the clinical doses. 
Dice similarity coefficients for the isodose volumes in Dc versus Dp,AB (blue) and Dp,AO 
(red) are presented in Figure 6.  The AB model clearly outperformed the AO model, with 
most isodose volumes having a Dice coefficient equal to or greater than 0.9, for both cross-
validation and testing. In particular, the AO model showed a poor accuracy for the isodose 
volumes in the medium to low dose region, i.e., Dice < 0.9 for the isodose volumes up to 60-
70% of the prescription dose, while the AB model achieves a Dice about 10% higher in the 
same region. In contrast, both models predicted the high dose region (from 80% isodose 
volume onwards) with comparable accuracy, though the AB model was still slightly superior, 
with Dice coefficients up to 2.5-5% higher than in the AO model. The lowest prediction 
accuracy occurs around the 40% isodose volume for both Dp,AB and Dp,AO, but this effect 
appears to be much more pronounced in the AO model. In addition, the color-wash band 
representing the standard deviation of the Dice coefficient across all patients is narrower for 
the AB model for both cross-validation and testing, indicating a more stable model.  
Figure 6 also includes the Dice similarity coefficients for the isodose volumes in Dc 
versus the input channel containing the beam representation for the AB model, i.e., the 
accumulated FCBB dose for all beams with the overwritten values inside the PTV equal to 
the prescription dose (Section 2.D). The FCBB dose alone seems to be an excellent 
approximation of Dc in the low and medium dose regions, with a Dice value of about 0.9. The 
difference between the prediction from the AB model and its input channel is nearly zero up 
to the 20% isodose volume, at which point it starts to increase (Figures 6.c and 6.d., yellow 
curve). This indicates that the AB model uses the input channel information as it is, without 
further modification, and learns how to include the modulation in the dose for each beam 
from the 20% isodose volume onwards. 
To illustrate the three-dimensional dose distribution predicted by the two models, we 
presented the results for one of the test patients in Figure 7: an axial slice located at the 
center of the target, as well as the corresponding DVH for Dc, Dp,AB, and Dp,AO. The rest of the 
patients are not presented here due to limited space in the manuscript, but the behavior is 
similar for all of them: the AO model predictions show a very isotropic dose gradient that 
uniformly decreases from the target to the edge of the body, while the AB model is able to 
capture the dose features along the beam path due to the additional beam setup 
information.  
The two models were trained across 150 epochs, which took about 15 hours in both 
cases. Additional training for a larger number of epochs was investigated but did not result in 
any improvement of the clinical DVH metrics under evaluation. The average prediction times 
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and their standard deviations were 11.42 ± 0.12 s per patient for the AO model and 11.66 ± 
0.14 s for the AB model, using one NVIDIA Tesla K80 card. The convergence of the two 
models is presented in Figure 8. The initial mean squared error for training and validation is 
much lower in the AB model (< 5) than in the AO model (> 14). This indicates that the 
prediction from the AB model is closer to the ground truth from the beginning, thanks to the 
extra input channel containing the beam setup information.  
 
 
 
  
Figure 4. Average absolute error on the mean (left) and maximum dose (right) for the predictions (Dp,AB 
and Dp,AO) versus the clinical dose (Dc) of all 5-fold models on the corresponding validation set for 
relevant organs in lung treatments. The black lines on top of the bars represent the standard deviation 
associated with each organ. 
 
 
  
Figure 5. Average absolute error on the mean (left) and maximum dose (right) for the predictions (Dp,AB 
and Dp,AO) versus the clinical dose (Dc) of all 5-fold models on the test set for relevant organs in lung 
treatments. The black lines on top of the bars represent the standard deviation associated with each 
organ. 
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Table 1. Mean absolute error and its standard deviation (mean±SD) for relevant DVH metrics on the 
target and on several organs for cross-validation (average prediction on the validation set for all 5 
folds), and testing (average prediction on the test set for all 5 folds), for the AO and AB models. The 
values are expressed as percentage of the prescription dose (Dpre = 60 Gy) for the metrics reporting 
the dose received by x% of volume (Dx), and as absolute difference for the metrics reporting the 
volume (in %) receiving a dose of y Gy (Vy).  
 
Mean absolute error for DVH metrics 
  
Cross-validation 
(mean ± SD) 
Testing 
(mean ± SD) 
  AO model AB model AO model AB model 
PTV 
D99 (% of Dpre) 3.36±3.24 2.70±3.06 3.50±2.96 2.54±2.56 
D98 (% of Dpre) 2.61±2.15 1.95±2.09 2.61±2.20 1.71±1.73 
D95 (% of Dpre) 1.80±1.25 1.10±0.86 1.92±1.34 1.08±0.96 
D5 (% of Dpre) 0.97±0.83 0.81±0.75 1.10±1.50 0.94±0.74 
Esophagus 
D2 (% of Dpre) 5.39±7.13 4.10±4.61 6.04±6.23 4.74±4.85 
V40 (% of volume) 4.99±5.57 3.25±3.77 4.74±5.09 3.58±4.90 
V50 (% of volume) 4.94±5.45 3.65±4.31 4.14±4.09 2.56±2.94 
Heart V35 (% of volume) 3.40±7.78 2.48±6.29 3.32±5.41 2.57±4.76 
Spinal cord D2 (% of Dpre) 10.10±7.82 6.74±6.10 7.64±7.12 5.05±4.10 
Lungs 
Dmean (% of Dpre) 2.21±1.61 1.12±1.00 2.04±1.68 1.13±0.94 
V5 (% of volume) 7.48±6.14 2.60±3.37 8.20±7.06 2.67±2.61 
V20 (% of volume) 3.96±3.66 2.18±2.42 4.66±4.51 2.67±2.87 
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Figure 6. The upper plots (a. and b.) contain the Dice similarity coefficients of the isodose volumes from 
5% to 95% of the prescription dose for Dp,AB (solid blue lines), Dp,AO (solid red lines), and the input 
channel of the AB model containing the FCBB dose (solid yellow lines), versus Dc, together with their 
corresponding average (dashed line) and standard deviation (color wash), for the 5-fold cross-validation 
(left) and testing (right). The bottom plots (c. and d.) contain the difference between the averaged Dice 
coefficient from the AB model versus the AO model (red line) and the FCBB dose used as input for the 
AB model (yellow line). 
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Figure 7. Illustration of an axial slice at the center of the target volume for one of the test patients: 
a) clinical dose (Dc), b) predicted dose from the AB model (Dp,AB), and c) predicted dose from the 
AO model (Dp,AO). Bottom plot (d) contains the DVHs for the three doses: solid lines correspond to 
the clinical dose (Dc), dashed lines to the prediction from AB model (Dp,AB), and dotted lines to the 
prediction from the AO model (Dp,AO). 
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Figure 8. Loss function (mean squared error) evaluated for the training (solid lines) and validation 
sets (dashed lines), for the AO (red) and AB models (blue). The lines correspond to the average 
value of the loss function for all 5 models obtained after the 5-fold cross-validation process, while 
the color-wash bands represent the associated standard deviation. 
 
We also tested and analyzed the AB and AO models for three additional patients with beam 
configurations that had not been included in the initial database used for the study (129 
patients, treated with 4 to 9 beams). The absolute mean error (over all 5 folds) on relevant 
DVH metrics for the doses predicted with the AB (Dp,AB) and AO models (Dp,AO) for these 
three patients are presented in Table 2. The AB model had lower prediction errors for most 
metrics and outperformed the AO model by more than 10% in some cases. For instance, the 
error on the heart V35 in patient #1 (treated with 3 coplanar beams) was 27% for the AO 
model but only 7% for the AB model. Similarly, the prediction error for the spinal cord D2 in 
patient #2 (treated with 11 coplanar beams) was 16% for the AO model but only 4% for the 
AB model; and the error for the lungs V5 in the same patient was 13% for the AO model and 
3% for the AB model. The differences were less pronounced in the case of patient #3 
(treated with 10 non-coplanar beams), but the AB model still outperformed the AO model’s 
prediction errors by 1% to 2% for most DVH metrics. These findings are confirmed by the 
Dice similarity coefficients on the isodose volumes, which are presented in Figure 9. The AB 
model outperformed the AO model by up to 20% in patients #1 and #2 in the low and 
medium dose regions, and by about 8% in patient #3. The full DVH curves for the three 
patients are also presented in Figure 10.  
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Table 2. Mean absolute error and its standard deviation (mean±SD) for relevant DVH metrics on the 
target and on several organs for the three patients used for additional testing (average prediction for 
all 5 folds), for the AO and AB models. The values are expressed as percentage of the prescription 
dose (Dpre = 60 Gy) for the metrics reporting the dose received by x% of volume (Dx), and as absolute 
difference for the metrics reporting the volume (in %) receiving a dose of y Gy (Vy).  
 
  Mean absolute error for DVH metrics 
  
P1 - 3 coplanar 
(mean ± SD) 
P2 - 11 coplanar 
(mean ± SD) 
P3 - 10 non-coplanar 
(mean ± SD) 
  AO model AB model AO model AB model AO model AB model 
PTV 
D99 (% of Dpre) 4.00±0.27 1.92±0.94 6.15±0.87 1.49±1.00 0.92±0.70 1.31±0.58 
D98 (% of Dpre) 3.10±0.44 1.27±0.75 4.55±0.81 1.24±0.36 1.03±0.76 0.90±0.50 
D95 (% of Dpre) 1.95±0.54 0.56±0.56 4.05±0.37 1.28±0.77 1.07±0.56 0.55±0.40 
D5 (% of Dpre) 1.42±0.45 1.94±0.47 2.01±0.47 0.72±0.32 1.07±0.53 0.18±0.16 
Esophagus 
D2 (% of Dpre) 0.73±0.24 0.79±0.46 2.54±1.26 1.80±1.62 - - 
V40 (% of volume) 1.79±1.44 2.50±0.51 0.00±0.00 0.00±0.00 - - 
V50 (% of volume) 1.67±1.25 2.08±0.93 0.00±0.00 0.00±0.00 - - 
Heart V35 (% of volume) 26.81±1.39 7.37±6.98 0.12±0.00 0.03±0.04 2.40±1.70 0.76±0.46 
Spinal cord D2 (% of Dpre) 2.72±1.36 3.64±2.60 15.81±2.33 3.60±3.36 2.73±2.41 3.13±2.90 
Lungs 
Dmean (% of Dpre) 3.05±1.69 1.05±0.51 1.83±0.16 0.65±0.65 2.26±2.27 0.43±0.35 
V5 (% of volume) 8.57±2.52 2.42±0.71 13.26±3.60 2.63±2.90 4.92±2.55 1.28±0.27 
V20 (% of volume) 5.97±2.50 0.85±0.86 0.65±0.74 0.49±0.48 4.69±6.09 2.24±0.59 
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P1 - 3 coplanar 
 
P2 - 11 coplanar 
 
P3 - 10 non-coplanar 
 
Figure 9. Dice similarity coefficients of the isodose volumes from 5% to 95% of the prescription dose for 
Dp,AB (solid blue lines), Dp,AO (solid red lines), and the input channel of the AB model containing the FCBB 
dose (solid yellow lines), versus Dc, together with their corresponding average (dashed line) and 
standard deviation (color wash), for the three test patients (averaged over all 5 folds). 
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a) P1 - 3 coplanar 
 
b) P2 - 11 coplanar 
 
 
c) P3 - 10 non-coplanar 
 
 
Figure 10. DVHs for the three patients considered (P#): solid lines correspond to the clinical dose 
(Dc), dashed lines to the prediction from AB model (Dp,AB), and dotted lines to the prediction from the 
AO model (Dp,AO). 
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4. DISCUSSION 
 
The AB model outperformed the AO model in all the evaluation criteria we considered, 
namely, DVH metrics and Dice similarity coefficients for the isodose volumes. The difference 
in the prediction error between the two models was rather small in the high dose region 
(around 1% of the prescription dose, on average), but major differences were found for the 
medium to low dose regions (up to the 60-70% isodose volumes), where the beam 
information actually plays an important role. For these regions, the AB model presented a 
Dice coefficient 10% better than the AO model. Another example of the AB model’s superior 
prediction accuracy for the low dose region is the lung volume receiving at least 5 Gy (V5), 
for which the prediction error was up to 5% lower than the AO model. Visual inspection of 
the predicted dose distributions from the two models also confirmed these results. The 
predictions from the AO model were unable to capture the dose features along the beam 
path, leading to a very uniform and isotropic dose fall-off. In contrast, the AB model 
accurately predicted the dose fingers corresponding to the different beam geometries.  
To compare the generalization ability of the AO and AB models, we also tested them in 
three additional patients from our clinic, with totally new beam configurations that were not 
included during training. The results showed that the AB model achieved a prediction error 
more than 10% lower than the AO model in some cases. These findings confirm the 
superiority of the AB model to the AO model, even for cases where the beam configuration 
differs from the ones included during training.  
The AB model was able to learn from a database that was heterogeneous in terms of 
beam configuration, by incorporating both anatomical and beam geometry information into 
the network. Our results suggest that by representing the beam configuration in the dose 
domain, we provide the model with valuable information about the dosimetric features that 
are not consistent through the database because of the variable beam arrangement. Thus, 
the model uses this elementary dosimetric information (FCBB) provided in the input channel 
and learns how to modulate it to achieve the optimal dose distribution for the given anatomy. 
The FCBB dose calculation used in this work is an improved ray-tracing type of algorithm, 
but we believe that any other elementary dose calculation algorithm can be used for the 
same purpose. Thus, the AB model represents an important step forward towards an easier 
and more robust implementation of automatic planning techniques, since it reduces the 
model’s dependence on consistent beam configuration characteristics through the training 
patient database. This is especially true for lung IMRT treatments, where tumors occur in 
different positions in the thorax, and their spatial relationships with other critical organs 
greatly vary from patient to patient, causing more variability in beam setup than in other 
tumor sites, such as prostate, where the beam configuration is relatively stable. Many other 
types of treatment could also benefit from this improved robustness against variable beam 
configuration, such as IMRT - 4𝜋 treatments for brain55 or liver,56,57 among others.58–60 
Regarding previous studies from other groups, the results obtained from the AB model 
(average error for the mean dose equal to 1.39±1.27%) are consistent with the values 
reported by McIntosh and Purdie,37 who achieved a mean average difference of 1.33% for 
their lung test set using a homogeneous beam configuration (all patients treated with VMAT). 
They did not report the prediction error for the maximum dose, which is often more 
challenging to predict than the mean dose, but we consider that our model achieved 
excellent accuracy for this metric too, since the average for all organs was 2.85±3.06% for 
the test set. In addition, the prediction of the low dose region may be better thanks to the 
supplementary beam setup information, even for models that used the same beam 
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configuration for all patients in the database. For instance, Moore et al.,34 using a database 
where all patients (prostate and brain) were treated with VMAT, reported up to 20 Gy of 
difference between the predicted and real doses for regions that were far from the PTV.  
In radiation therapy treatment planning, the sum of the square difference between the 
planned and the prescription dose is often used as the loss function.1 This prompted us to 
use the MSE between the predicted and the clinically delivered doses as the loss function in 
our study. In addition, using MSE is computationally cheap and leads to a convex 
optimization problem with a stable gradient, which is easier to solve than non-convex 
problems. However, investigating the use of other metrics as loss functions, such as the 
inclusion of DVH metrics for target and organs, may be an interesting field of study.  
The time needed to predict the three-dimensional dose distribution per patient was 
similar for the two models: AB model (11.66 ± 0.14 s) and AO model (11.42 ± 0.12 s). The 
time employed to compute the FCBB dose used as input to the model can be considered 
negligible since it was less than one second.53 In addition, the FCBB dose per beam can 
later be used to feed the optimizer52 in the treatment planning system employed to generate 
the plan. The predicted 3D dose matrix can then be used as a voxel-wise objective to create 
a treatment plan that mimics it.35,41,43 Since the most advanced optimizers can provide a 
solution within seconds, the total time required to generate a full plan may be kept under a 
minute, if the right hardware is used. This provides a good environment to implement online 
adaptive strategies,9 where the plan needs to be adapted while the patient is on the 
treatment couch, and every extra minute is of crucial importance. In addition, the presented 
model could be used as part of beam angle optimization strategies for IMRT, by generating 
3D doses for different beam configurations and then selecting the optimal one according to 
DVH metrics or any other relevant criteria used in the clinic for plan evaluation. In this 
context, the generated doses could also serve as planning guidance for the dosimetrist or 
even as a decision support tool for the treating physician before going to treatment planning. 
Eventually, the dose prediction model could be used in tumor board meetings for 
comparison with other suitable treatments and could assist in evaluating tumor control 
probability and possible secondary effects.  However, as is the case with every deep 
learning application, one must be aware of the importance of the quality of the database 
used for training. If the ground truth doses are suboptimal, the predicted doses will be 
suboptimal too, i.e., the garbage in, garbage out paradigm. Therefore, the medical 
community should encourage the construction of high quality databases created by 
experienced planners, which can serve to improve and standardize future clinical practice. 
Meanwhile, the best solution might be the use of human-assisted and dynamic workflows, 
where the models are trained with the existing databases (heterogeneous plan quality) and 
used under the supervision of physicians. The physicians will then select the highest quality 
results, which will be used later to update and improve the current models. 
Lastly, the dose prediction models in the existing literature have been applied so far to 
radiation therapy treatments with photons, i.e., IMRT or VMAT. However, extending these 
models to proton therapy represents an extra challenge, given the sensitivity of the dose 
distribution to heterogeneities in the tissue traversed. In this context, providing the model 
with basic beam setup information along the beam path is essential, and we believe our 
model could be easily applied for that purpose, which we plan to study in a future work. 
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5. CONCLUSION 
 
We used deep neural networks to build a model that can learn from a database of 
previous patients treated with variable beam configuration and predict the three-dimensional 
dose distribution for a new patient. Two models were trained and compared: the first model 
(AO) only accounted for the anatomy of the patient, while the second model (AB) included 
both anatomical and beam setup information, the latter being represented in the dose 
domain. The AB model showed greater accuracy and robustness against variable beam 
geometry than the AO model. This suggests that using a three-dimensional matrix containing 
elementary dose features along the beam paths as input to the model will help to achieve a 
more comprehensive automatic planning based on deep neural networks without the need to 
train specific models for every beam arrangement.  
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